Daniel Garrett Vail, MD
Ophthalmology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Hospitals listed: UC San Diego Health Hillcrest - Hillcrest Med Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Vail’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UC San Diego Health Hillcrest - Hillcrest Med CtrSan Diego, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Moores Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 105.39 (74.34 to 136.44) · 381 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.597, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.618, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.376, Oct 2024 – Sep 2025
See every measure and the patient survey for UC San Diego Health Hillcrest - Hillcrest Med Ctr
Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 105.39 (74.34 to 136.44) · 381 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.597 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.618 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.376 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.83 (0.11 to 1.54) · 3,862 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.84 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 510 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11 · 696 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 435 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 5,739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.32) · 12,387 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.44) · 13,596 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.59 (3.24 to 5.94) · 4,389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.04 (0 to 2.12) · 2,419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.26 (1.23 to 3.29) · 4,116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.93 (6.61 to 13.25) · 2,232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.31 (5.24 to 9.38) · 2,410 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.32 (1.07 to 3.56) · 1,286 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0.02 to 0.75) · 11,838 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 181 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.672 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 302 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.3 · 891 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 216 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.9 · 620 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 12 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 946 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.8 to 7) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.7 to 14) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.1 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.7 · 177 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.4 (8.5 to 13) · 4,116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1) · 2,130 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,680 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$28,690
Medicare paid this office $28,690 for 191 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 164 | $18,553 | $109 |
| New patient complete exam of visual system | 13 | $1,691 | $130 |
Who their Medicare patients are
191 Original Medicare patients in 2024. Average age 77 · Women 61% · Also on Medicaid 14% · Health risk score 1.45. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 29% · Coronary heart disease 26% · Chronic kidney disease 23% · Heart failure 19% · Atrial fibrillation 18% · Depression 17% · Cancer 16% · COPD 16% · Dementia 8% · Stroke 8%.
The office billed $141,104, Medicare allowed $36,303 and paid $28,690; for 337 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$749 in 2024
Medicaid paid $749 for 22 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 22 | $749 |
| 2024 | 22 | 1 | 22 | $749 |
Drugs they prescribed that Part D paid
$38,846
Pharmacies billed $38,846 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 383) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
203 generic and 180 brand-name prescriptions · $38,846 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rhopressa | 37 | $11,926 | $322 |
| Brimonidine | 52 | $3,174 | $61 |
| Combigan | 12 | $2,864 | $239 |
| Prednisolone Acetate | 63 | $1,811 | $29 |
| Dorzolamide-Timolol | 50 | $719 | $14 |
See all 8 drugs
| Rhopressa | 37 | $11,926 | $322 |
| Brimonidine | 52 | $3,174 | $61 |
| Combigan | 12 | $2,864 | $239 |
| Prednisolone Acetate | 63 | $1,811 | $29 |
| Dorzolamide-Timolol | 50 | $719 | $14 |
| Moxifloxacin | 15 | $347 | $23 |
| Ketorolac Tromethamine | 11 | $283 | $26 |
| Latanoprost | 47 | $277 | $6 |
Year by year
| 2024 | 383 | 102 | 0% (0) | 47% | $38,846 |
| 2023 | 446 | 142 | 0% (0) | 36% | $51,781 |
| 2022 | 1,308 | 278 | 0% (0) | 38% | $146,439 |
| 2021 | 386 | 96 | 0% (0) | 50% | $46,529 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Restasis | 14 | $9,891 | $707 |
| Rhopressa | 14 | $7,531 | $538 |
| Brimonidine | 52 | $4,493 | $86 |
| Dorzolamide-Timolol | 73 | $2,003 | $27 |
| Prednisolone Acetate | 57 | $1,658 | $29 |
| Latanoprost | 89 | $1,424 | $16 |
| Moxifloxacin | 12 | $499 | $42 |
| Dorzolamide | 11 | $452 | $41 |
| Ketorolac Tromethamine | 17 | $386 | $23 |
2022: 16 drugs
| Rhopressa | 74 | $27,820 | $376 |
| Restasis | 29 | $21,289 | $734 |
| Brimonidine | 225 | $16,663 | $74 |
| Lumigan | 32 | $11,502 | $359 |
| Combigan | 24 | $10,231 | $426 |
| Dorzolamide-Timolol | 218 | $8,003 | $37 |
| Brinzolamide | 20 | $6,972 | $349 |
| Latanoprost | 338 | $6,796 | $20 |
| Alphagan P | 15 | $6,680 | $445 |
| Prednisolone Acetate | 69 | $2,543 | $37 |
| Pilocarpine | 30 | $2,376 | $79 |
| Dorzolamide | 38 | $1,355 | $36 |
| Valacyclovir | 15 | $511 | $34 |
| Timolol Maleate | 37 | $384 | $10 |
| Ketorolac Tromethamine | 15 | $340 | $23 |
| Erythromycin | 16 | $152 | $10 |
2021: 8 drugs
| Rhopressa | 32 | $10,474 | $327 |
| Brimonidine | 53 | $4,985 | $94 |
| Lumigan | 15 | $3,376 | $225 |
| Durezol | 11 | $2,335 | $212 |
| Prednisolone Acetate | 34 | $1,836 | $54 |
| Latanoprost | 72 | $1,521 | $21 |
| Dorzolamide-Timolol | 40 | $1,461 | $37 |
| Timolol Maleate | 17 | $149 | $9 |
Money from drug and device companies
$381 in 2025
| 2025 | 6 | 8 | None | $381 |
| 2024 | 3 | 6 | None | $1,193 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mallinckrodt Hospital Products | Acthar | $106 | 1 payment
|
| Astellas Pharma Global Development | Izervay | $79 | 1 payment
|
| Astellas Pharma US | Izervay | $67 | 2 payments
|
| Bausch & Lomb Americas | Xipere | $58 | 1 payment
|
| Amgen | Tepezza | $49 | 2 payments
|
| Abbvie | Ozurdex | $21 | 1 payment
|
See all 8 published payments
| Bausch & Lomb Americas | Meals · 2025-10-22 | Xipere | $58 |
| Astellas Pharma Global Development | Meals · 2025-10-01 | Izervay | $79 |
| Astellas Pharma US | Meals · 2025-09-16 | Izervay | $35 |
| Abbvie | Meals · 2025-09-09 | Ozurdex | $21 |
| Astellas Pharma US | Meals · 2025-08-12 | Izervay | $32 |
| Amgen | Meals · 2025-06-04 | Tepezza | $27 |
| Amgen | Meals · 2025-04-23 | Tepezza | $22 |
| Mallinckrodt Hospital Products | Meals · 2025-03-19 | Acthar | $106 |
See earlier years (2024)
2024: $1,193
| Alcon Vision | None | $1,044 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $121 | 1 payment
|
| Abbvie | Ozurdex | $28 | 1 payment
|
Professional record
- NPI
- 1285262568
- Trained
- Stanford University School of Medicine, 2020
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
- NPI first listed
- 2020-03-31
- NPI last updated
- 2026-08-11
- NPI record certified
- 2026-08-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9300 Campus Point Dr, La Jolla, CA, 92037 · 9415 Campus Point Dr, La Jolla, CA, 92093 · 3020 Childrens Way, San Diego, CA, 92123 · 300 Pasteur Dr, Stanford, CA, 94305